Hypogammaglobulinemia: a diagnosis that must not be overlooked

Overview of attention for article published in Brazilian Journal of Medical and Biological Research, January 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#9 of 1,254)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 15 news outlets

twitter: 2 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 51 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 15 news stories from 15 outlets.

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Biz Wire Express, 26 Sep 2023

Takeda Pharmaceutical Company Limited (BusinessWire India) 2023-09-26 Business Wire India Takeda (TSE:4502/NYSE:TAK) today…

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Businessfortnight, 26 Sep 2023

Osaka, Japan

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Etnet.com.hk, 26 Sep 2023

Approval is Based on Clinical Studies Conducted in Japan, Europe and North America Confirming the Efficacy and Safety of…

Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Pharmaceutical Daily, 25 Sep 2023

Approval is Based on Clinical Studies Conducted in Japan, Europe and North America Confirming the Efficacy and Safety of…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 11 additional news stories.